Tag: ACS
TCT 2019: Apixaban plus a P2Y12 inhibitor is the optimal strategy for AF with ACS and/or PCI
A prespecified analysis of data from the AUGUSTUS study, released at late-breaking session at th...
Adrian Banning
Adrian Banning (John Radcliffe Hospital, Oxford, UK) initially wanted to fly a Boeing 747 but, aged ...
Alirocumab receives EC approval in established atherosclerotic cardiovascular disease
The European Commission (EC) has approved the use of alirocumab (Praluent, Sanofi), a PCSK9 inhibito...
Age is a strong predictor of spontaneous myocardial infarction in medically managed patients
Renato D Lopes (Division of Cardiology, Department of Medicine, Duke University School of Medici...
